MedPath

Phase 2 study of RK-023 patients with androgenetic alopecia (male pattern baldness) -A study for safety and preliminary estimation of hair re-growth in male subjects with androgenetic alopecia treated for 13 weeks with RK-023

Phase 2
Conditions
Androgenetic alopecia (male pattern baldness)
Registration Number
JPRN-jRCT2080220997
Lead Sponsor
R-Tech Ueno, Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
Male
Target Recruitment
48
Inclusion Criteria

Men aged between 20 and 44 years with an androgenetic alopecia rated as Takashima modified classification of Norwood-Hamiltonstage, IIv, IIIv and IV

Exclusion Criteria

Subjects with the complication that treatment is required

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber of cases with side-effects (Safety), change for anagen hair ratio (Efficacy)<br>Clinical valuation (Safety)<br>Phototrichogram (Efficacy)
Secondary Outcome Measures
NameTimeMethod
Global photograph of vertex (Efficacy)<br>Global photograph of vertex
© Copyright 2025. All Rights Reserved by MedPath